Salius Pharma Expands High-Quality API Supply to Africa

 

 

“Targeting East and West African nations including Kenya, Tanzania, Uganda, Ethiopia, Ghana, Nigeria, Ivory Coast, Botswana, and Gabon“

 

Mumbai, India – July 26, 2025

 

Continuing its vision to enhance worldwide access to low-cost, high-quality drugs, Salius Pharma, a top Indian Pharmaceutical Active ingredients supplier globally , today declared its next international expansion phase on premium Active Pharmaceutical Ingredients (APIs) in strategic East and West African countries.

The firm will give top priority to API supply to Kenya, Tanzania, Uganda, Ethiopia (East Africa), and Ghana, Nigeria, Ivory Coast, and Gabon (West Africa) nations with increasing demand for sophisticated pharma formulations and increased investment in domestic drug productio.

 

“Africa is a cornerstone of our global growth strategy,” said a senior representative of Salius Pharma.

 

“We are consolidating our presence on the continent with a focused supply of high-quality, regulatory-compliant APIs to serve both private and public sector formulators.”

 

High-End APIs Focus for Key Therapeutic Segments

 

Salius Pharma is expanding its product range in Africa to include high-end APIs used in chronic and specialty treatments, including:

Antiretrovirals (ARVs): Zidovudine, Lamivudine.

 

Cardiovascular APIs: Atorvastatin, Telmisartan, Rosuvastatin.

 

Antidiabetic APIs: Metformin, Sitagliptin, Glimepiride, Empagliflozin.

 

Oncology and CNS APIs (available on request): Gefitinib, Letrozole.

 

Anti-infectives and antibiotics: Gabapentin, Pregabalin, Escitalopram.

 

All APIs are manufactured in WHO-GMP, USFDA, and EU-compliant facilities and are shipped with full regulatory support, including DMFs, CTD dossiers, and stability data, facilitating faster registration and tender participation across African markets.

 

Promoting API Access and Local Manufacturing

 

Africa is undergoing a constant shift in pharma infrastructure, with government and local manufacturers looking for trusted API partners to minimize reliance on imported finished formulations.

 

For this purpose, Salius Pharma is:

 

• Convergence with local formulation partners in Kenya, Nigeria, Ghana, and Ethiopia.
  
  
• Engagement with public health procurement agencies and hospital procurement chains.
  
  
• Assisting in local dossier preparation and regulatory submissions.
  
  

• Providing tailor-made packaging and flexible batch quantities.

 

“Our ambition is not merely to export APIs, but to become a long-term facilitator of Africa‘s self-sufficiency in healthcare production,” the spokesperson went on.

 

Constructing Partnerships Across Africa

 

Salius Pharma extends an open invitation to African government agencies, local pharma players, importers, and distributors to identify long-term business opportunities under its API partnership umbrella. Salius Pharma will also take part in top African pharma expos and regulatory meetings in the next year.

 

 

Media Contact:

Salius Pharma Pvt. Ltd.
Email: info@saliuspharma.com
Website: www.saliuspharma.com
Phone: +91-8425880640